Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
measles + rubella
- Development stage
- Phase 3
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
The measles + rubella vaccine (MR) is a live attenuated combination vaccine used to confer immunity against measles and rubella. It is a core component of the National Immunisation Programme in China, where it is typically administered as a 0.5 ml subcutaneous injection to infants at 8 months of age. The vaccine contains attenuated strains of both the measles virus (Morbillivirus) and the rubella virus. Clinical trials, including those co-sponsored by the China CDC and the US CDC, have demonstrated that the MR vaccine can be safely co-administered with other childhood vaccines, such as the live attenuated Japanese encephalitis vaccine (LJEV), without compromising the immunogenicity or safety profile of either component.
- Brand names
- MR-Vac
- Other names
- MR vaccineMeasles-Rubella combined vaccineMeasles-Rubella vaccine
02
Targets
CD46 (CD46 Molecule)MV (Measles virus)PVRL4 (Nectin cell adhesion molecule 4)
Beyond the preview
Go deeper on measles + rubella.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on measles + rubella.